Study of pz-cel treatment for wounds from epidermolysis bullosa
Part of Genetic & congenital, Skin clinical trials.
This study evaluates pz-cel, a personalized skin cell treatment for wounds caused by dystrophic epidermolysis bullosa (a genetic condition causing fragile skin). It provides access to the treatment when the manufactured product doesn't meet standard release, or for patients needing special access, and helps ensure its safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have dystrophic epidermolysis bullosa (DEB) and are expected to receive pz-cel (Prademagene Zamikeracel), a treatment that uses your own skin cells to help heal wounds.
- You must be willing to sign a consent form, or have a parent or guardian do so if you are under 18.
- You are not allergic to the antibiotics vancomycin or amikacin.
- You do not have an active infection (such as HIV, hepatitis B or C, or a body-wide infection).
- Depending on the study part: you must either have a non-conforming batch of pz-cel, need a biopsy before treatment, or need special access to the treatment.
- If you are a woman who could become pregnant, you must agree to use reliable birth control and not be breastfeeding (in some study parts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This study is a follow-up safety study for people who have already completed an earlier trial of SD-101 for epidermolysis bullosa (a condition causing fragile skin). It aims to check the long-term safety of the treatment.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.